Cushing Syndrome Market size to grow by USD 616.66 million from 2023 to 2028; The glucocorticoid receptor antagonists segment is estimated to witness significant growth during the forecast period. - Technavio

NEW YORK, Nov. 7, 2023 /PRNewswire/ -- The cushing syndrome market is expected to grow by USD 616.66 million from 2023 to 2028. In addition, the market's momentum will progress at a CAGR of 14.7% during the forecast period, according to Technavio Research. The market is segmented by type (glucocorticoid receptor antagonists, pituitary-directed drugs, and steroidogenesis inhibitors), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read a Free PDF Sample Report

North America is estimated to contribute 86% to the growth of the global market during the forecast period. The US and Canada are the main countries of North America which have a strong presence in this region. Market growth is being positively influenced by factors such as the availability of Cushing syndrome drugs like Isturisa (osilodrostat), Korlym (mifepristone), and Recorlev (levoketoconazole) in the region. 

Company Profile:

Corcept Therapeutics Inc., Perrigo Co. Plc, Recordati S.p.A, and Xeris Biopharma Holdings Inc. are key companies.

Corcept Therapeutics Inc - The company offers treatment for Cushing syndrome such as KORLYM mifepristone 30g tablets.

To access more company profiles available with Technavio, buy the report!

Cushing Syndrome Market: Segmentation Analysis

The glucocorticoid receptor antagonists segment is estimated to witness significant growth during the forecast period. Mifepristone is essentially a US-based FDA-approved drug classified under glucocorticoid receptor antagonists for the treatment of Cushing syndrome.

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report

"Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio

Cushing Syndrome Market: Market Dynamics

• Growing geriatric population
• Rising drug development for Cushing syndrome treatment
• Favorable reimbursement scenario of Cushing syndrome treatment

Key Driver

The growing geriatric population is a key factor driving market growth. The cost of healthcare is an important burden for older people. Moreover, spending patterns on health care in advanced and developing countries will change considerably over the next few decades due to an aging population.

The increasing growth potential in emerging economies is a major trend in the market. Identify key trends, drivers, and challenges in the market. Download to gain access to this information.

Related Reports:

The anti-CD20 monoclonal antibodies (mABs) market size is estimated to grow by USD 11,425.15 million at a CAGR of 10.31% between 2023 and 2028. 

The upper respiratory tract infection treatment market size is estimated to grow by USD 2,661.15 million at a CAGR of 4.21% between 2023 and 2028. Top players in the market would be encouraged to concentrate on developing drugs that treat upper tract infections given the high prevalence of these infections. In the pipeline, a number of late-stage molecules are likely to be launched over the next few years. 

What are the key data covered in this Cushing Syndrome Market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the cushing syndrome market between 2023 and 2028.
• Precise estimation of the cushing syndrome market size and its contribution to the market in focus on the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the cushing syndrome market across North America, Europe, Asia, and ROW
• A thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of cushing syndrome market companies.

ToC:

Executive Summary

Market Landscape

Market Sizing

Historic Market Sizes

Five Forces Analysis

Market Segmentation by Type

Market Segmentation by Distribution Channel

Market Segmentation by Geography

Customer Landscape

Geographic Landscape

Drivers, Challenges, & Trends

Company Landscape

Company Analysis

Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com

SOURCE Technavio